Quick answer
SS-31, elamipretide, and Forzinity are connected names, but they do not carry identical meaning in every context. SS-31 is the research name commonly used for the peptide. Elamipretide is the name used throughout clinical development. Forzinity is a specific named elamipretide hydrochloride product in an FDA record for a narrow Barth syndrome population.1
That regulatory story does not turn every earlier study positive or authenticate every SS-31 listing. Trials in primary mitochondrial myopathy and an eye condition missed their main endpoints, while a small Barth syndrome extension and exploratory subgroups reported narrower positive findings.23456
Why do three names appear in one research story?
Names often change as a molecule moves from laboratory work into clinical development and a named product record.
“SS-31” helps readers find early and mechanistic research. “Elamipretide” appears in clinical trial reports across several conditions. “Forzinity” points to one specific regulated product and application.
The shared history is useful for searching. The differences are essential for interpreting a claim.
A laboratory result under SS-31 does not establish a clinical outcome. An elamipretide trial in one disease does not prove an effect in another. A Forzinity record does not authenticate an unrelated catalog item.
Good writing uses the name that matches the source, then explains the connection without erasing the boundary.
Search results can mix all three names on one page, so a date and disease filter helps reconstruct the sequence. Early mechanism papers, clinical trial reports, and a later regulatory snapshot serve different purposes even when they concern the same molecule.
Aliases improve discovery; they do not make the underlying evidence interchangeable.
Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.
What does the Forzinity record cover?
The FDA record identifies Forzinity as elamipretide hydrochloride under application NDA215244 for a narrow Barth syndrome indication.1
The source applies to the named product, eligible population, and regulatory conditions. It is not a general approval of “SS-31” as an online category.
The record also describes a very small evidence program in a rare disease. Population size, endpoint history, and continuing evidence requirements belong in any accurate summary.
Regulatory status and broad scientific proof are not synonyms. A named product may have a defined indication while studies in other diseases remain negative or exploratory.
Filipino readers should also avoid treating a US record as a Philippine product registration. Local and overseas records answer different jurisdictional questions.
What did the Barth syndrome extension report?
An open-label extension of TAZPOWER followed a very small group with Barth syndrome.
Ten patients entered the extension and eight completed the 168-week visit. The report described a cumulative 96.1-meter improvement on the six-minute walk test.2
That is a positive long-term finding in the observed group. It came from an open-label extension without a concurrent placebo group, so time, selection, continued participation, and other factors cannot be separated as cleanly as in a blinded randomized phase.
The six-minute walk test measures distance under standardized conditions. It does not represent every symptom or daily activity.
Rare-disease studies can be small for understandable reasons. The limitation should be stated without dismissing the participants or inflating the certainty.
What happened in primary mitochondrial myopathy?
MMPOWER-3 was a 24-week randomized, double-blind, placebo-controlled phase 3 trial in 218 adults with primary mitochondrial myopathy.
Elamipretide did not significantly improve the primary six-minute walk or total fatigue endpoints compared with placebo.3
That main result must remain visible. A positive title, mechanism discussion, or later subgroup cannot rewrite the prespecified endpoints as successful.
Afterward, investigators examined genetic subgroups. Participants with certain nuclear-DNA replisome variants showed a trend toward improvement, and a narrower subgroup with chronic progressive external ophthalmoplegia showed a larger difference.45
These post hoc findings are exploratory because the groups were identified after the main trial analysis. They can guide a prospective study but cannot independently overturn the failed primary result.
What did the eye trial find?
A phase 2 trial tested a topical elamipretide eye solution in 12 people with Leber hereditary optic neuropathy.
The 52-week randomized, vehicle-controlled, double-masked study found the treatment well tolerated but did not show a significant difference in best-corrected visual acuity between treated and vehicle eyes.6
A post hoc analysis suggested a possible signal among people with a shorter duration of vision loss. That observation requires further study and should not be reported as the main trial result.
The formulation also matters. A topical ophthalmic solution answers a different question from a systemic product or catalog listing.
This trial belongs in the story because it shows that one molecule can have separate programs with distinct routes, diseases, and outcomes.
How should positive and negative findings be combined?
Lead with the study’s design and primary result.
For MMPOWER-3 and the eye trial, the primary endpoints were not met. For the Barth extension, a positive walk-distance change occurred in a small open-label group. Subgroup findings remain exploratory.
This is not a contradiction. A molecule can produce different results across populations, formulations, endpoints, and study designs.
Avoid averaging the studies into “works” or “does not work.” Instead, map each finding to the exact disease, phase, comparator, and outcome.
That approach is more informative than collecting only favorable sentences. It also prevents a narrow regulatory status from becoming a universal benefit claim.
What should Filipino readers verify?
Search all three names when reviewing the research, then check which name and formulation the source actually studied.
The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products. Search the exact product and company rather than assuming a foreign record carries over locally.7
WHO explains that some falsified products can closely resemble genuine ones and may require quality-control analysis. A familiar research name cannot establish an item’s contents.8
The catalog card below the article is not the Forzinity product record and makes no equivalence claim.
Keep every conclusion attached to its source, disease, formulation, study context, jurisdiction, and product identity.9
Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.
Bottom line
SS-31, elamipretide, and Forzinity trace one development history, but each name carries a different scope. The FDA record covers a named product and narrow Barth syndrome context. A small open-label extension reported improved walk distance, while phase 3 primary mitochondrial myopathy and phase 2 eye trials missed their primary efficacy endpoints.
Later subgroup findings remain exploratory. Filipino readers should use the names to find the complete record, not to merge every formulation, disease, study result, or catalog item into one claim.
Frequently asked questions
Are SS-31 and elamipretide related names?
Yes. SS-31 is a research name, while elamipretide is used in clinical development.
Is Forzinity every product labeled SS-31?
No. It is a specific named product in an FDA record.1
Did MMPOWER-3 meet its main endpoints?
No. The walk and fatigue endpoints were not significantly improved versus placebo.3
Were any positive findings reported?
Yes, including a small Barth extension and exploratory PMM subgroups, each with important limits.245
Does the SS-31 card claim equivalence to Forzinity?
No. It is a neutral catalog reference and is not the named FDA product.
Sources
Footnotes
-
FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE). Official FDA Drug Trials Snapshot and application record for the named product. The record applies only to the named FDA-regulated product, eligible population, and indication; it does not establish equivalence for a catalog item. ↩ ↩2 ↩3
-
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. This result comes from a long-term extension study where 10 patients entered and 8 completed the 168-week visit. The improvement was statistically significant (P = .003). This was an open-label study with no placebo group, and the number of participants was very small. ↩ ↩2 ↩3
-
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.. The MMPOWER-3 trial was a 24-week, randomized, double-blind, placebo-controlled study. The primary endpoints were the change in 6MWT distance and the PMM Symptom Assessment total fatigue score. ↩ ↩2 ↩3
-
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.. This was an unplanned analysis after the main trial failed. The improvement of 25.2 meters vs. 2.0 meters for placebo had a p-value of 0.06. Post hoc analyses are exploratory and cannot prove efficacy on their own. This finding requires confirmation in a new prospective trial. ↩ ↩2 ↩3
-
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.. This was a further post hoc analysis of the MMPOWER-3 trial, with a p-value of 0.0024. This finding comes from a very specific, small subgroup identified after the trial was completed and needs prospective validation. ↩ ↩2 ↩3
-
Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.. This was a 52-week, randomized, vehicle-controlled, double-masked trial. The primary efficacy endpoint was not met. The study was small, and a post hoc analysis suggested a potential benefit in patients with a shorter duration of vision loss, which would need further study. ↩ ↩2
-
Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩
-
WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩
-
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.; Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.; Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩
